### **Expansion of different subpopulations of CD26**-/low T cells in allergic

## 2 and non-allergic asthmatics.

#### 3 Authors

- 4 Juan José Nieto-Fontarigo<sup>1</sup>, Francisco Javier Salgado\*<sup>1</sup>, María Esther San-José<sup>2</sup>, María Jesús
- 5 Cruz<sup>3</sup>, Luis Valdés<sup>4</sup>, Amparo Pérez-Díaz<sup>5</sup>, Pilar Arias<sup>1</sup>, Montserrat Nogueira<sup>1</sup>, Francisco Javier
- 6 González-Barcala<sup>6</sup>.

#### 7 Affiliations:

- <sup>1</sup>Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research
- 9 Centre (CIBUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
- <sup>2</sup>Clinical Analysis Service, USC University Hospital Complex (CHUS), Santiago de
- 11 Compostela, Spain.
- <sup>3</sup>Department of Respiratory Medicine-Hospital Vall d'Hebron, Universitat Autònoma de
- 13 Barcelona, Barcelona, Spain. Spanish Biomedical Research Networking Centre-CIBERES.
- <sup>4</sup>Department of Medicine-University of Santiago de Compostela; Department of Respiratory
- 15 Medicine-University Hospital of Santiago de Compostela; Health Research Institute of Santiago
- de Compostela (IDIS).
- 17 <sup>5</sup>Drug Screening Platform/Biofarma Research Group, Molecular Medicine and Chronic
- 18 Diseases Research Center, University of Santiago de Compostela, Santiago de Compostela,
- 19 Spain.
- <sup>6</sup>Department of Medicine-University of Santiago de Compostela, Department of Respiratory
- 21 Medicine-University Hospital of Santiago de Compostela, Spanish Biomedical Research
- Networking Centre-CIBERES; Health Research Institute of Santiago de Compostela (IDIS).

### 23 Corresponding author:

- Francisco Javier Salgado Castro. Biology of Lymphocyte Group (BioLympho). Department of
- 25 Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS),

- Universidade de Santiago de Compostela, Campus Vida, C/ Lope Gómez de marzoa s/n,
- 27 Santiago de Compostela, Spain. E-mail: Phone: +34 881816941.
- 28 **Supplementary Tables:** 4
- 29 **Supplementary Figures:** 6

# Supplementary Table S1. Correlation of CD26 and CD126 expression with the % of different leukocyte subsets.

	Correlation between the % of cells and the % of CD26+ cells in each subpopulation		Correlation between the % of cells and the % of CD126+ cells in each subpopulation		
	$r_{\rm s}$	P	$r_{\rm s}$	P	
Eosinophils	181	.003	.205	<.001	
Monocytes	206	<.001	085	.168	
Neutrophils	.041	.500	.035	.564	
Lymphocytes	103	.094	057	.354	
CD4 cells	312	<.001	353	<.001	
CD4 <sup>+</sup> cells	.367	<.001	.211	<.001	
Teff cells	.469	<.001	.247	<.001	
Treg cells	.023	.702	070	.254	
Tlow cells	342	<.001	360	<.001	

Supplementary Table S2. Severity and control degree of the study patients.					
	IMA	MSA		CA	UA
N	102	90	1	158	34
Age (mean (range))	44 (20-72)	41 (18-68)		45 (18-72)	45 (20-68)
Sex (M/F)	33/69	35/55		59/99	9/25
FEV1 (%)	105.0 (95.0- 113.3)***	86.5 (67.0-100.0)		99.0 (87.0-111.0)*	82.0 (60.7-100.0)
FEV1/FVC (%)	77.5 (72.5- 81.2)***	70.3 (59.5-78.5)		76.4 (69.0-80.5)*	70.0 (56.4-76.8)
Neutrophils (10 <sup>3</sup> cells/μL)	3.60 (3.09-4.23)	3.62 (2.88-4.40)		3.58 (3.07-4.23)	4.17 (2.78-5.00)
Lymphocytes (10 <sup>3</sup> cells/μL)	1.97 (1.65-2.25)	1.97 (1.64-2.54)		1.95 (1.60-2.26)	2.02 (1.86-2.74)
Monocytes (10 <sup>3</sup> cells/μL)	0.39 (0.30-0.48)	0.39 (0.32-0.49)		0.38 (0.30-0.49)	0.41 (0.32-0.48)
Eosinophils (10 <sup>3</sup> cells/μL)	0.26 (0.17-0.39)*	0.33 (0.21-0.48)		0.27 (0.18-0.40)*	0.38 (0.21-0.63)
Basophils (10 <sup>3</sup> cells/μL)	0.04 (0.02-0.05)	0.04 (0.03-0.05)		0.04 (0.02-0.05)	0.04 (0.03-0.06)
IgE (IU/mL)	45.5 (15.5-205.0)	84.0 (28.2-209.5)		79.0 (20.5-200.0)	62.0 (24.7-274.0)

CA, controlled asthmatics; IMA, intermittent-mild asthmatics; MSA, moderate-severe asthmatics; UA,  $uncontrolled\ as thmatics.$ 

Data are presented as median value (IQR1-3), unless otherwise expressed. Mann-Whitney U test was used to compare IMA vs. MSA and CA vs. UA. \* P < 0.05; \*\*\* P < 0.001


## Supplementary Table S3. Average expression of CD26 and CD126 molecules in different leukocyte subsets and the half-life of these cells in peripheral circulation.

	Eosinophils	Monocytes	Neutrophils	Lymphocytes
Absolute count (x10 <sup>3</sup> cells/mL)	0.04-0.4	0.2-0.8	2.5-7.5	1.5-3.5
% of CD126 <sup>+</sup> cells*	63.4 (44.5- 77.5)	78.5 (52.2- 91.0)	99.5 (98.8- 99.8)	55.3 (48.6- 61.3)
% of CD26 <sup>+</sup> cells*	2.1 (1.4-3.2)	7.4 (3.5- 17.6)	11.9 (5.0- 27.7)	59.2 (54.4- 66.4)
Half-life in peripheral blood <sup>#</sup>	8-18 h	22-24 h	6 h - 5 days	days-years


<sup>\*</sup>Median value (IQR1-3).

<sup>\*</sup>Data come from Pillay J, et al. Blood. 2010;116:625-7; Park YM, et al. Allergy Asthma Immunol Res. 2010;2:87-101; Patel AA, et al. J Exp Med. 2017;214:1913-1923; Robertson JM, et al. Immunol Rev. 2006;211:49-57.


Supplementary Table S4. List of monoclonal antibodies used in flow cytometry assays.					
Target	Clone	Fluorophore	Provider	Cat. no	
CD3	UCHT1	FITC	BD Pharmigen <sup>TM</sup>	555332	
CD4	RPA-T4	FITC	BD Pharmigen <sup>TM</sup>	555346	
CD25	M-A251	PE-Cy7	BD Pharmigen <sup>TM</sup>	5135905	
CD127	HIL-7R-M21	AlexaFluor-647	BD Pharmigen <sup>TM</sup>	558598	
CD3	UCHT1	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	560835	
CD8	RPA-T8	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	560662	
CD19	HIB19	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	561295	
CD27	M-T271	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	560612	
CD28	CD28.2	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	560685	
CD45RA	HI100	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	563429	
CD56	B159	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	560842	
CD197 (CCR7)	150503	PerCP-Cy5.5	BD Pharmigen <sup>TM</sup>	561144	
TCR-γ/δ	B1	FITC	Biolegend	331207	
CD26	TP1/19	PE	Immunostep	PE26 100T	
CD126 (IL-6Rα)	REA291	PE	MACS Miltenyi Biotec	130-104-101	



Supplementary Figure S1. Rhinitic and asthmatic patients show augmented levels of CD127<sup>+</sup> regulatory T cells. Lymphocytes from healthy controls (HC; N = 32) and patients with rhinitis (R; N = 44), allergic asthma (AA; N = 100), and non-allergic asthma (NAA; N = 92) were gated on FSC/SSC plots and further subdivided into CD4<sup>-</sup> and CD4<sup>+</sup> cells. Then, regulatory T cells (Treg) were identified amongst CD4<sup>+</sup> T lymphocytes according to CD25 and CD127 markers. Afterwards, the percentage of CD127<sup>+</sup> cells within the Treg compartment was measured. Statistically significant difference between the different groups of donors is indicated (P < .05).



**Supplementary Figure S2.** Treg cells are distributed within CD26<sup>-/low</sup> and CD26<sup>int</sup> subsets of CD4<sup>+</sup> T cells. a) Lymphocytes from healthy controls (HC) and patients with rhinitis (R), allergic asthma (AA), and non-allergic asthma (NAA) were gated on FSC/SSC plots and further subdivided into CD4<sup>-</sup> and CD4<sup>+</sup> cells. Then, 3 subsets of CD4<sup>+</sup> lymphocytes were identified based on CD26 and CD127 markers: CD26<sup>-/low</sup>, CD26<sup>int</sup> and CD26<sup>high</sup>. As figures **b-d** point out, Treg cells (CD25<sup>high</sup>CD127<sup>low</sup>) are present in CD26<sup>-/low</sup> (b) and CD26<sup>int</sup> (c) subsets of CD4<sup>+</sup> T lymphocytes, but not amongst the CD26<sup>high</sup> compartment of T helper cells (d).



Supplementary Figure S3. CD4 lymphocytes with a CD126 CD127 phenotype are increased in non-allergic asthmatics (NAA) compared to allergic asthmatics (AA). a) CD4 lymphocytes were identified through the gating strategy depicted (left and middle dot-plots), and expression of CD127 and CD126 was used to identify four subsets (right dot plot). b) Lymphocyte subset composition of CD4<sup>-</sup>CD126<sup>-</sup>CD127<sup>-</sup> and CD4<sup>-</sup>CD126<sup>+</sup>CD127<sup>+</sup> cells based on CD3 (T), CD8 (Tc), CD19 (B), and CD56 (NK, NKT) antigens. c) Phenotype of CD4 CD126 CD127 and CD4 CD126 CD127 cells based on CD45RA, CCR7, CD127, CD28, and CD27 markers. We evidenced that the former CD26<sup>int</sup>CD127<sup>+</sup> and CD26<sup>high</sup>CD127<sup>+</sup> subsets were combined in one single CD4 population (CD126 CD127 cells), with a homogeneous naïve-memory CD3<sup>+</sup> and CD8<sup>+</sup> phenotype. In contrast, the CD126 CD127 subset comprised T<sub>EMRA</sub>-like cells (CD45RA high CCR7 low CD27 low CD28 low), but a less-defined CD4 lymphoid origin (B, NK, NKT, or  $\gamma\delta$ -T cells). In **b**) and **c**), data were obtained from 3 representative donors. d) Percentage (median ± IQR) of CD126 CD127 and CD126 CD127 cells in CD4 lymphocytes from healthy controls (HC; N = 32) and patients with rhinitis (R; N = 44), allergic asthma (AA; N = 100), and non-allergic asthma (NAA; N = 92). Like CD4<sup>-</sup>CD26<sup>+</sup>CD127<sup>+</sup> lymphocytes, CD4 CD126 CD127 cells were reduced in NAA compared to AA, which was associated to the expansion of the double negative (CD126 CD127) compartment in NAA. Only results from those subpopulations with significant differences between donor groups were shown. Statistically significant differences between groups of donors were indicated (Kruskal-Wallis test: P < .05).

54 55

56

57

58

59

60 61

62

63

64


65

66


67

68 69

70 71




Supplementary Figure S4. Gating strategy for CD8<sup>+</sup> Tc, NK, NKT,  $\gamma\delta$ -T, and B lymphocytes. After gating, expression of CD127 and CD26 was used to identify different subsets (lower row of dot-plots). CD3<sup>+</sup> lymphocytes (Tc, NKT,  $\gamma\delta$ -T) were characterized by the presence of three subsets (CD26<sup>-/low</sup>, CD26<sup>int</sup>, and CD26<sup>high</sup>), while CD3<sup>-</sup> lymphocytes displayed a double (CD26<sup>-/low</sup>, CD26<sup>int</sup>; NK cells) or a single (CD26<sup>-:</sup> B cells) phenotype.



Supplementary Figure S5. Moderate-severe non-allergic asthmatics display higher percentage of  $CD26^+$  regulatory T cells than intermittent-mild non-allergic asthmatics. Lymphocytes from either moderate-severe non-allergic (MSNAA; N = 90) or intermittent-mild non-allergic (IMNAA; N = 102) asthmatics were gated on FSC/SSC plots and further subdivided into  $CD4^-$  and  $CD4^+$  cells. Then, regulatory T cells (Treg) were identified amongst  $CD4^+$  T lymphocytes according to CD25 and CD127 markers. Afterwards, the percentage of  $CD26^+$  cells within the Treg compartment was measured. Statistically significant difference

between the different groups of donors is indicated (*P*-value).



Supplementary Figure S6. Analysis of the number of cell divisions by flow cytometry. PBMCs were stained with 5  $\mu$ M CFSE and cultured at 0.25 x 10<sup>6</sup> cells/mL in complete medium (RPMI 1640, 10% FBS, 100  $\mu$ g/mL streptomycin, 100 U/mL penicillin) supplemented with 1  $\mu$ g/ml PHA as a T-cell specific polyclonal stimulus. Upon 6 days of *in vitro* culture, CFSE fluorescence decay was measured by flow cytometry and allowed the calculation of the number of cell divisions. A representative histogram plot is shown, where numbers 1-6 represent the corresponding round of division, and 0 those lymphocytes that remained at a resting state. Responder frequency (Rf) was calculated as the percentage of cells that divided at least once (i.e., percentage of cells that divide from 1 to 6 times).